FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137235816> ?p ?o ?g. }

• W3137235816 endingPage "586" @default.
• W3137235816 startingPage "575" @default.
• W3137235816 abstract "Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev®), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, was one of the first drugs approved for use in idiopathic pulmonary fibrosis (IPF) and has more recently been approved for use in other chronic fibrosing ILDs with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). In multinational phase III trials, nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) in adults with IPF, other progressive fibrosing ILDs and SSc-ILD. Reductions in FVC decline with nintedanib in patients with IPF and severe gas exchange impairment were comparable to those in patients with milder disease. Real-world experience in patients with IPF supports the effectiveness of nintedanib in slowing ILD progression. Nintedanib had a manageable tolerability profile in patients with fibrotic ILDs in clinical trials and real-world studies. No new safety signals have emerged from global pharmacovigilance data. Nintedanib continues to represent an important therapeutic option in patients with IPF and is the first drug to be approved for use in patients with other chronic fibrosing ILDs with a progressive phenotype or SSc-ILD, with these approvals expanding the range of fibrotic ILDs for which nintedanib can be prescribed.Treatment options for fibrotic interstitial lung diseases (ILDs) that involve progressive lung function decline have historically been limited. Nintedanib (Ofev®) was one of the first antifibrotic drugs to be approved for use in idiopathic pulmonary fibrosis and is now also approved for use in other chronic fibrosing ILDs with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). Nintedanib reduced lung function deterioration in patients with idiopathic pulmonary fibrosis, other chronic fibrosing ILDs with a progressive phenotype and SSc-ILD in well-designed clinical trials. In patients with idiopathic pulmonary fibrosis, the clinical benefit of nintedanib was shown to persist over more than 4 years of treatment. The most common adverse events in nintedanib recipients were diarrhoea and nausea, which were manageable in the majority of patients. Real-world experience supports the effectiveness and acceptable safety of nintedanib. Nintedanib remains an important treatment option for patients with idiopathic pulmonary fibrosis and is the first drug to be approved for use in patients with other chronic fibrosing ILDs with a progressive phenotype and SSc-ILD." @default.
• W3137235816 created "2021-03-29" @default.
• W3137235816 creator A5047338174 @default.
• W3137235816 date "2021-03-25" @default.
• W3137235816 modified "2023-10-10" @default.
• W3137235816 title "Nintedanib: A Review in Fibrotic Interstitial Lung Diseases" @default.
• W3137235816 cites W1757222072 @default.
• W3137235816 cites W1938547050 @default.
• W3137235816 cites W1975158384 @default.
• W3137235816 cites W1981253900 @default.
• W3137235816 cites W2002064506 @default.
• W3137235816 cites W2089756110 @default.
• W3137235816 cites W2119115210 @default.
• W3137235816 cites W2120791222 @default.
• W3137235816 cites W2138871107 @default.
• W3137235816 cites W2147322791 @default.
• W3137235816 cites W2152974152 @default.
• W3137235816 cites W2159148154 @default.
• W3137235816 cites W2164134225 @default.
• W3137235816 cites W2234165587 @default.
• W3137235816 cites W2267642110 @default.
• W3137235816 cites W2469138893 @default.
• W3137235816 cites W2474839550 @default.
• W3137235816 cites W2507379588 @default.
• W3137235816 cites W2524005801 @default.
• W3137235816 cites W2549071917 @default.
• W3137235816 cites W2614444402 @default.
• W3137235816 cites W2750186979 @default.
• W3137235816 cites W2753035500 @default.
• W3137235816 cites W2753114974 @default.
• W3137235816 cites W2753358475 @default.
• W3137235816 cites W2767226776 @default.
• W3137235816 cites W2788452276 @default.
• W3137235816 cites W2790696411 @default.
• W3137235816 cites W2794423021 @default.
• W3137235816 cites W2810699055 @default.
• W3137235816 cites W2811389906 @default.
• W3137235816 cites W2889828413 @default.
• W3137235816 cites W2890575335 @default.
• W3137235816 cites W2901074800 @default.
• W3137235816 cites W2901235303 @default.
• W3137235816 cites W2904388381 @default.
• W3137235816 cites W2906077632 @default.
• W3137235816 cites W2906713537 @default.
• W3137235816 cites W2920766120 @default.
• W3137235816 cites W2925251455 @default.
• W3137235816 cites W2941614408 @default.
• W3137235816 cites W2943019980 @default.
• W3137235816 cites W2945521814 @default.
• W3137235816 cites W2947366664 @default.
• W3137235816 cites W2974960379 @default.
• W3137235816 cites W2979280297 @default.
• W3137235816 cites W2999054805 @default.
• W3137235816 cites W3003269956 @default.
• W3137235816 cites W3010166382 @default.
• W3137235816 cites W3010685062 @default.
• W3137235816 cites W3013021754 @default.
• W3137235816 cites W3040518023 @default.
• W3137235816 cites W3047341706 @default.
• W3137235816 cites W3047777264 @default.
• W3137235816 cites W3083040024 @default.
• W3137235816 cites W3119924984 @default.
• W3137235816 cites W572470369 @default.
• W3137235816 doi "https://doi.org/10.1007/s40265-021-01487-0" @default.
• W3137235816 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8163683" @default.
• W3137235816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33765296" @default.
• W3137235816 hasPublicationYear "2021" @default.
• W3137235816 type Work @default.
• W3137235816 sameAs 3137235816 @default.
• W3137235816 citedByCount "37" @default.
• W3137235816 countsByYear W31372358162021 @default.
• W3137235816 countsByYear W31372358162022 @default.
• W3137235816 countsByYear W31372358162023 @default.
• W3137235816 crossrefType "journal-article" @default.
• W3137235816 hasAuthorship W3137235816A5047338174 @default.
• W3137235816 hasBestOaLocation W31372358161 @default.
• W3137235816 hasConcept C126322002 @default.
• W3137235816 hasConcept C142724271 @default.
• W3137235816 hasConcept C197934379 @default.
• W3137235816 hasConcept C2777543607 @default.
• W3137235816 hasConcept C2777714996 @default.
• W3137235816 hasConcept C2778341716 @default.
• W3137235816 hasConcept C2778375690 @default.
• W3137235816 hasConcept C2779832356 @default.
• W3137235816 hasConcept C2780171596 @default.
• W3137235816 hasConcept C71924100 @default.
• W3137235816 hasConceptScore W3137235816C126322002 @default.
• W3137235816 hasConceptScore W3137235816C142724271 @default.
• W3137235816 hasConceptScore W3137235816C197934379 @default.
• W3137235816 hasConceptScore W3137235816C2777543607 @default.
• W3137235816 hasConceptScore W3137235816C2777714996 @default.
• W3137235816 hasConceptScore W3137235816C2778341716 @default.
• W3137235816 hasConceptScore W3137235816C2778375690 @default.
• W3137235816 hasConceptScore W3137235816C2779832356 @default.
• W3137235816 hasConceptScore W3137235816C2780171596 @default.
• W3137235816 hasConceptScore W3137235816C71924100 @default.
• W3137235816 hasIssue "5" @default.
• W3137235816 hasLocation W31372358161 @default.

• next